@lab_keller

We aim at identifying mechanisms of cancer pathogenesis to develop novel mechanism-based and molecular-informed cancer therapies

Joined February 2020
  • Tweets26
  • Following93
  • Followers122
1Media
💡Möglicher neuer Ansatz gegen #Bauchspeicheldrüsenkrebs: Wie eine #CharitéBerlin-Studie jetzt zeigt, führt die gleichzeitige Blockade zweier voneinander abhängiger „Zahnrädchen“ in der Krebszelle zur Hemmung des Tumorwachstums – zumindest im Tiermodell.👉charite.de/forschung/paper_s…
Tumor der Bauchspeicheldrüse nach Kombinationsbehandlung. Sie bewirkt, dass die Fresszellen des Immunsystems (Makrophagen; gelb) nicht mehr das Tumorwachstum fördern, sondern seine Bekämpfung durch das Immunsystem stimulieren © Charité | Zuzana Tatarova

ALT Tumor der Bauchspeicheldrüse nach Kombinationsbehandlung. Sie bewirkt, dass die Fresszellen des Immunsystems (Makrophagen; gelb) nicht mehr das Tumorwachstum fördern, sondern seine Bekämpfung durch das Immunsystem stimulieren © Charité | Zuzana Tatarova

1
11
23
1,584
Early View | Haematologica haematologica.org/article/vi… Finally first results from our Phase 1 TCR study targeting MAGE-A1 in myeloma! Hopefully more to come in advanced solid tumors where need for innovative (cellular) therapies is still HUGE.
2
6
470
Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…

Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus | NEJM

A woman with aggressive refractory systemic lupus erythematosus was treated with a short course of the bispecific antibody teclistamab (anti–B-cell maturation antigen and anti-CD3) and had a drug-...

nejm.org
4
1
10
1,779
Keller-Lab@Charite retweeted
Science Signaling@scisignal26 Feb 2024
Engineering a mouse model of #autoimmunity, researchers at @ChariteBerlin have made strides in understanding the basis of a mysterious and rare autoimmune disorder named STAT3GOF syndrome and identified sex-specific differences in the disorder. @lab_keller scim.ag/60n
2
5
975
Keller-Lab@Charite retweeted
Science Signaling@scisignal21 Feb 2024
Researchers generated a new mouse model of #STAT3GOF syndrome that can recapitulate the IL-6-gp130-STAT3 pathway and multi-organ autoimmunity—addressing the lack of reliable animal models for this rare autoimmune condition. @lab_keller @ChariteBerlin scim.ag/5Xp
1
2
687
Keller-Lab@Charite retweeted
Eilers Lab@MYCGyvers1 Dec 2023
CIAO @_WolfLab 🤍 Today we say goodbye to Anneli and Elmar after more than a decade in the institute. Both of you shaped our institute and the science done @Uni_WUE! We wish you all the best for your new adventure @kieluni!
2
17
1,028
Check out our recent publication in EMBO Mol Med: Actionable loss of SLF2 drives B-cell lymphomagenesis and impairs the DNA damage response embopress.org/doi/full/10.15…
2
3
9
1,258
Great opprtunity for a postdoctoral researcher/team leader at Keller-Lab@Charite karriere.charite.de/stellena… Looking forward to your application!
2
4
726
We are looking for a talented PhD student. See our announcement at Charité Homepage and Jobvector!
3
In Annals of Oncology, results from the German 🇩🇪 #PrecisionMedicine 🧬🎯💊 NCT/DKTK MASTER trial inform on the association of cancer perdisposing genes and rare cancer annalsofoncology.org/article…
60
8
155
Dr. Uta Demel von #CharitéBerlin und @MDC_Berlin ist für eine ihrer Publikationen mit dem Forschungspreis der Arbeitsgemeinschaft DAG-HSZT ausgezeichnet worden. Herzlichen Glückwunsch! charite.de/forschung/themen_…
1
1
15
Keller-Lab@Charite retweeted
GRK2243@grk22439 May 2022
It's not all about #ubiquitin: Listen to Uta Demel from @lab_keller @MDC_Berlin how inhibition of SUMOylation leads to increased antigen presentation and T-cell activation
1
3
A team of researchers from #CharitéBerlin reveal in @jclinicalinvest how cancer cells can evade immunosurveillance. A cellular signaling pathway activated as part of this process may offer a new target for more effective cancer immunotherapy treatments. jci.org/articles/view/152383
2
9
New treatment strategy for #PancreaticCancer: Writing in @PNASNews, a team of researchers from #CharitéBerlin describe how a key factor which enables the suppression of cancer cell death (#apoptosis) can be used to block #TumorGrowth. charite.de/en/service/press_…
3
7
Writing in @NatureComms, a team of researchers from #CharitéBerlin and @goetheuni untangle a key process involved in #Lymphoma development, which controls DNA damage repair and offers a potential treatment target. charite.de/en/service/press_…
2
5
Richie, Stefan and coworkers reveal a critical role for CXCR4 in aggressive forms of CLL : nature.com/articles/s41375-0…
1
1
1
5
Keller-Lab@Charite retweeted
Özcan Çınar@cinar_ozcan30 Jul 2021
After years of hard work (literally) involving blood, sweat and tears, I am thrilled to be able share this! We developed TCRs targeting one of the most common mutations in #lymphoma. Online at @jitcancer : jitc.bmj.com/content/9/7/e00… @MDC_Berlin @ChariteBerlin

High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of...

Background Adoptive transfer of engineered T cells has shown remarkable success in B-cell malignancies. However, the most common strategy of targeting lineage-specific antigens can lead to undesira...

jitc.bmj.com
1
3
1
21
Important preclinical study to advance tumor-specific adoptive T cell therapy for patients with MYD88 mutant lymphoma. Congratulations to Antonia Busses group jitc.bmj.com/content/9/7/e00…

High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of...

Background Adoptive transfer of engineered T cells has shown remarkable success in B-cell malignancies. However, the most common strategy of targeting lineage-specific antigens can lead to undesira...

jitc.bmj.com
1
3
Keller-Lab@Charite retweeted
Ricardo Lange@RicardoLange418 May 2021
Sorry, für heute muss ich erst einmal weg. Ich bin echt enttäuscht und fassungslos zugleich. Mit Beleidigungen kann ich umgehen, aber einige Wortmeldungen sind für mich echt harter Tobak.
298
103
16
3,123
After 20 years of preliminary research in the labs of @MDC_Berlin & #CharitéBerlin, a new T-cell immunotherapy against #MultipleMyeloma is now in clinical trials. The innovative treatment is designed to teach the immune system to fight the cancer cells. charite.de/en/service/press_…
2
14
Load more